From the Journals

Berberine Evaluated for Liver Fat

Six-month randomized trial finds no reduction in visceral or hepatic fat in patients with obesity and MASLD

Share

  • 1

    Berberine did not reduce VAT or liver fat in non-diabetic patients with MASLD.

  • 2

    337 patients participated in the trial across 11 hospitals.

  • 3

    The trial lasted for 6 months with a 1 g daily dosage of berberine.

  • 4

    Significant reductions in LDL cholesterol and hs-CRP levels were noted.

  • 5

    Safety profile of berberine was found to be excellent, with no serious adverse events reported.

Original Source(s)

Berberine Evaluated for Liver Fat

Six-month randomized trial finds no reduction in visceral or hepatic fat in patients with obesity and MASLD

  • by Jo Cavallo

  • February 12, 2026

  • 2 min

Related Content

Oral GLP-1s Won’t Win on Convenience – They’ll Win on CMC 

GLP-1 peptides validated the science. CMC will validate the small molecule modality for GLP-1 efficacy, scalability, and access.

GLP-1 Analysis: Riding the Wave of Peptide Innovation

The remarkable commercial success of GLP-1 receptor agonists is fueling investment, accelerating science, and creating new analytical challenges. Here, we outline the hurdles these peptides present, explore methods for impurity profiling and structural characterization, and consider strategies to keep pace with this fast-moving field.

Oxytocin’s Role in Obesity Management

Researchers review human data on oxytocin’s effects on appetite, satiety, and metabolic health